2-S-cysteinylhydroquinone is an Intermediate for the Firefly Luciferin Biosynthesis that Occurs in the Pupal Stage of the Japanese Firefly, Luciola lateralis

• The first Cys+BQ adduct in the luciferin pathway is identified directly in the animal. Working in Luciola lateralis pupae, the authors detected 2-S-cysteinylhydroquinone, the Michael-addition product of L-cysteine onto p-benzoquinone, captured in its reduced hydroquinone form. This is the chemical identity of the first dedicated intermediate downstream of the BQ pool, and it had previously been inferred only from in vitro chemistry (Kanie 2016) rather than observed in vivo.
• Pupae, not adults, are the synthesis stage. The lantern of an adult firefly is essentially a glow organ running on luciferin laid down earlier; this paper localizes the actual biosynthetic activity to the pupal stage when the light organ is being built. That timing matters mechanistically, it means the enzymes (and the substrates BQ + Cys) are being co-expressed in a developmentally specific context, which is part of why the pathway has been hard to reconstruct from adult lantern transcriptomes alone.
• The chemistry of the first conjugation is consistent with spontaneous Michael addition. Hydroquinone oxidizes to benzoquinone, benzoquinone is a soft electrophile, and a thiol like cysteine adds across the ring without needing an enzyme, this is textbook Michael chemistry and has been demonstrated to occur in buffer (Kanie 2016). The 2018 paper closes the loop: the same adduct that forms spontaneously in vitro is the one that accumulates in vivo. Whether a dedicated firefly enzyme accelerates this step or whether it runs on intrinsic reactivity remains formally open, but the chemistry is permissive.
• Same species, same isotope-tracer toolkit as Oba 2013. The continuity matters, Oba's 2013 work in adult L. lateralis showed two L-Cys + one BQ → luciferin by stable-isotope LC/ESI-TOF-MS, and this paper uses compatible methodology to extend the picture into pupae and to nail down the first intermediate. Together they form a coherent biochemical case: BQ pool (from arbutin/HQ) → cysteinyl-HQ adduct (Cys #1) → onward steps requiring a second Cys addition, cyclizations, and oxidation to give luciferin.
• Steps after 2-S-cysteinylhydroquinone are still unmapped. The paper identifies one intermediate but does not resolve the full sequence to luciferin, the second Cys addition, the benzothiazoline ring closures, and the final oxidation to the dehydroluciferin/ luciferin redox state remain mechanistically open. Some of those steps (especially the cyclizations) are plausibly enzyme-assisted given their stereochemistry, and that is exactly the gap into which candidates like PPYR_02911 fit.

Bottom line for the project: This paper is the in vivo evidence that the first committed step of luciferin biosynthesis after BQ formation is a chemically simple Cys-Michael addition, which is good news for the heterologous N. tabacum build, it suggests the first Cys+BQ conjugation may not require a dedicated firefly enzyme and could proceed on intrinsic reactivity once BGLU46 (TU3) liberates HQ from arbutin and PPYR_02911 (TU2) handles the HQ → BQ oxidation. That collapses one potential gene from the minimum set. The flip side is that the downstream steps from 2-S-cysteinylhydroquinone to luciferin are still unaccounted for, and that is where your candidate roster (PPYR_02911 as a P450 doing more than one job, or backup candidates like PPYR_05464) has to do real work. Worth citing whenever you justify why TU2 through TU4 plus endogenous tobacco cysteine is a defensible minimum pathway, while being honest in the same breath that the post-adduct chemistry is not yet enzymatically resolved.